NEW YORK, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will report financial results for the first quarter ended December 31, 2015 after the market close on Tuesday, February 9, 2016. The Company will also hold a live investor conference call and webcast at 5:00pm Eastern.
| Conference Call & Webcast | |
| Tuesday, February 9 at 5:00pm Eastern Time | |
| Domestic: | 877-407-0789 |
| International: | 201-689-8562 |
| Conference ID: | 13629898 |
| Webcast with Slides: | http://public.viavid.com/index.php?id=118193 |
| Replays – Available through February 16, 2016 | |
| Domestic: | 877-870-5176 |
| International: | 858-384-5517 |
| Conference ID: | 13629898 |
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is an ophthalmology research and development company. The company's lead product, OHR-102 (Squalamine Lactate Ophthalmic Solution, 0.2%), is currently being studied as an eye drop formulation in clinical trials for back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information on the company may be found at www.ohrpharmaceutical.com.